Stifel Nicolaus

As beverage companies compete to grow their non-carbonated drinks divisions, energy drink companies have often been subject to buyout rumors. A terminated distribution agreement between an energy drink company and a leading beverage company is leading to more merger and acquisition speculation in...

The Street leans bullish on Biogen Inc (NASDAQ: BIIB), and one sidelined analyst doesn’t want to miss on the profits. The Rating Stifel Nicolaus analyst Paul Matteis resumed coverage of Biogen with a Buy rating and $394 price target. The Thesis Biogen’s fate is seen to hinge...

Casella Waste Systems Inc. (NASDAQ: CWST) missed bottom-line estimates last week and suffered a 6-percent plunge in share price. The stock recovered its losses and then some, but one Wall Street firm tossed the trash company to the side. The Rating Stifel Nicolaus analyst Michael Hoffman...

Despite exceeding bottom-line expectations, NewLink Genetics Corp (NASDAQ: NLNK) plummeted Wednesday on second-quarter sales that were nearly 50 percent below projections.  Stifel Nicolaus sees little visibility for NewLink going forward.  The Rating Stifel Nicolaus analyst Stephen...

MEI Pharma Inc (NASDAQ: MEIP) is down 31.5 percent from its one-year high struck after the release of preliminary data for ME-401. Stifel Nicolaus considers the decline a stake-building opportunity. The Analyst  Analyst Stephen Willey upgraded MEI from Hold to Buy and raised the...

IBM (NYSE: IBM) reported second-quarter earnings Wednesday, narrowly beating consensus estimates for both EPS and sales. Investors responded positively for the most part, though some commentators did express concerns about the details.  The Analysts Morgan Stanley’s Katy Huberty...

Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) a shot in the arm with an ultrabullish rating, Stifel Nicolaus administered a booster. Galmed spiked 15 percent Friday morning after already having risen 21 percent in the preceding session. The Analyst ...

Furniture retailer Conn’s Inc (NASDAQ: CONN) shares saw a strong recovery in June that bulls expect to continue through the next year. The Rating Stifel Nicolaus analyst John Baugh upgraded Conn’s from Hold to Buy and raised the price target from $35 to $45. The Thesis...

The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday.  The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but...

Ascendis Pharma A/S (NASDAQ: ASND) shares are up 180 percent year-over-year, but one analyst thinks the Street hasn’t been generous enough. The Analyst  Stifel Nicolaus analyst Adam Walsh initiated coverage on Ascendis with a Buy rating and $85 price target. The Thesis By Walsh...

Dr Pepper Snapple Group Inc. (NYSE: DPS) is expected to be subsumed by Keurig Green Mountain in July. The stock has maintained substantial gains since the first merger announcement, and Stifel Nicolaus thinks it couldn’t do any better. The Rating Analysts Mark Swartzberg, Christopher Sinnott...

Pre-open movers U.S. stock futures traded lower in early pre-market trade. Data on housing starts for May will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average fell 339 points to 24,677.00, while the Standard & Poor’s 500 index futures traded declined 30.25 points...

Stryker Corporation (NYSE: SYK) has approached Boston Scientific Corporation (NYSE: BSX) with a buyout opportunity, according to The Wall Street Journal. Boston Scientific shares spiked 11 percent on the initial report and were subsequently halted with news pending. Stryker plunged 3.3 percent...

Wyndham Hotels & Resorts Inc (NYSE: WH) spun off from Wyndham Worldwide on Thursday, liberating it from a range-bound stock and providing fresh room to run, according to Stifel Nicolaus. The Rating Analysts Simon Yarmak and Alexander Fraser initiated coverage with a Buy rating and $68 price...